Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases

Endothelial Fli1 Deficiency Impairs Vascular Homeostasis

(2010) Yoshihide Asano et al.   AMERICAN JOURNAL OF PATHOLOGY

Imatinib Mesylate Has The Potential to Exert Its Efficacy by Down-Regulating The Plasma Concentration of Platelet-Derived Growth Factor in Patients With Pulmonary Arterial Hypertension

(2010) Masaru Hatano et al.   International Heart Journal

Future treatments in systemic sclerosis

(2010) Yoshihide ASANO   JOURNAL OF DERMATOLOGY

Imatinib for refractory chronic graft-versus-host disease with fibrotic features

(2009) A. Olivieri et al.   BLOOD

Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension

(2009) Henrik ten Freyhaus et al.   Clinical Research in Cardiology

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphorylation of Fli1 at Threonine 312 by Protein Kinase C   Promotes Its Interaction with p300/CREB-Binding Protein-Associated Factor and Subsequent Acetylation in Response to Transforming Growth Factor  

(2009) Y. Asano et al.   MOLECULAR AND CELLULAR BIOLOGY

A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate

(2009) S Bhattacharyya et al.   ONCOGENE

Transcription Factor Fli1 Regulates Collagen Fibrillogenesis in Mouse Skin

(2008) Y. Asano et al.   MOLECULAR AND CELLULAR BIOLOGY

Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

(2008) Jo N. Fleming et al.   PLoS One

Imatinib for the treatment of refractory, diffuse systemic sclerosis

(2008) P. P. Sfikakis et al.   RHEUMATOLOGY